Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic Group
- 1 October 2011
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 31 (10) , 735-743
Abstract
Background and Objectives: Pitavastatin is a highly effective lipid-lowering drug (approved dose range 1–4 mg/day) with a distinctive metabolic pathway that has a low potential for drug interactions. The efficacy and safety of pitavastatin have been characterized in a broad clinical development programme conducted initially in Japanese patients. The objectives of the present study were to evaluate the pharmacokinetic bioequivalence of the European (EU) and Japanese (JP) formulations of pitavastatin 2mg in healthy Japanese and Caucasian men, and to assess whether the bioavailability of each formulation was similar in the two ethnic groups. Methods: In this open-label, single-dose, two-way crossover pharmacokinetic study, healthy men aged 18–45 years were randomized to receive: the JP formulation of pitavastatin 2 mg followed by the EU formulation; or the EU formulation of pitavastatin 2mg followed by the JP formulation. The main outcome measures were maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) during a dosage interval (τ) [AUCτ] and AUC from time zero to infinity (AUC∞) for pitavastatin and its main (inactive) metabolite pitavastatin lactone. Plasma concentrations of pitavastatin and pitavastatin lactone were determined using a validated liquid chromatography-tandem mass spectrometry method. Results: Forty-eight Caucasian and 12 Japanese men completed the study. Compared with the Japanese men, the Caucasian men were of greater mean body weight (76.1 vs 58.9 kg), height (180.8 vs 170.8 cm) and body mass index (23.2 vs 20.2 kg/m2). Geometric mean ratios (GMRs) of the pharmacokinetic parameters of pitavastatin demonstrated bioequivalence of the EU and JP formulations: GMRs and 90% confidence intervals (CIs) fell within the range 80–125% in Caucasian men and in Caucasian and Japanese groups combined for pitavastatin Cmax (combined analysis: GMR 103.1% [90% CI 96.0, 110.6]), AUCτ (GMR 99.6% [90% CI 95.5, 104.0]), and AUC∞ (GMR 104.2% [90% CI 96.2, 112.8]). After adjusting for age and body weight in the pooled formulation analysis, bioequivalence between the Caucasian and Japanese groups was similarly demonstrated for pitavastatin Cmax (GMR 96.8% [90% CI 90.2, 103.8]), AUCτ (GMR 98.3% [90% CI 94.2, 102.7]) and AUC∞ (GMR 85.9% [90% CI 81.1, 91.0]). Conclusion: The EU and JP formulations of pitavastatin showed pharmacokinetic bioequivalence, and there were no clinically relevant differences in exposure to pitavastatin between Caucasian and Japanese participants when differences in body weight were taken into account.Keywords
This publication has 15 references indexed in Scilit:
- Pitavastatin – pharmacological profile from early phase studiesAtherosclerosis Supplements, 2010
- Exploring Differences in Drug Doses Between Japan and Western CountriesClinical Pharmacology & Therapeutics, 2010
- Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patientsActa Pharmacologica Sinica, 2010
- OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteersJournal of Clinical Pharmacy and Therapeutics, 2010
- The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapyThe Pharmacogenomics Journal, 2009
- Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goalsVascular Health and Risk Management, 2009
- Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemiaCurrent Medical Research and Opinion, 2009
- Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) StudyJournal of Atherosclerosis and Thrombosis, 2009
- A Review and Assessment of Potential Sources of Ethnic Differences in Drug ResponsivenessThe Journal of Clinical Pharmacology, 2003
- Molecular Basis of Ethnic Differences in Drug Disposition and ResponseAnnual Review of Pharmacology and Toxicology, 2001